Drug Trial Radar · NCT07416461
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Oct 27, 2025
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- International Vaccine InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 18, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5. Eligible participants residing in the Kisantu Health Zone (DRC) and presenting fever are enrolled in healthcare facilities and tested for malaria and iNTS. Using a case-control (test-negative) design, the researchers will look at the malaria vaccination status of participants with and without iNTS infection to determine if the malaria vaccine protects against iNTS.
Conditions
- Invasive Non-Typhoidal Salmonella Disease
- Malaria
- Malaria Vaccine
Interventions
R21/Matrix-M malaria vaccineBiological
R21/Matrix-M malaria vaccination was introduced by DRC Ministry of Public Health in the Expanded Program on Immunizations on 29th of October 2024. Children aged 6 months to 24 months are eligible to receive the vaccine. Vaccination follows a 4 doses schedule: a first dose administered between 6 and 11 months of age, a second dose one month after the first dose, a third dose one month after the second dose and a booster dose seven months after the third dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood culture-confirmed iNTS disease (including malaria co-infections) in participants who received complete malaria vaccination vs. unvaccinated participants.Time frame: At presentation (enrollment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut National de Recherche Biomedicale (INRB)
Kinshasa, Democratic Republic of the Congo · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.